10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dual role of pericyte α6β1-integrin in tumour blood vessels

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          The α6β1-integrin is a major laminin receptor, and formation of a laminin-rich basement membrane is a key feature in tumour blood vessel stabilisation and pericyte recruitment, processes that are important in the growth and maturation of tumour blood vessels. However, the role of pericyte α6β1-integrin in angiogenesis is largely unknown. We developed mice where the α6-integrin subunit is deleted in pericytes and examined tumour angiogenesis and growth. These mice had: (1) reduced pericyte coverage of tumour blood vessels; (2) reduced tumour blood vessel stability; (3) increased blood vessel diameter; (4) enhanced blood vessel leakiness, and (5) abnormal blood vessel basement membrane architecture. Surprisingly, tumour growth, blood vessel density and metastasis were not altered. Analysis of retinas revealed that deletion of pericyte α6-integrin did not affect physiological angiogenesis. At the molecular level, we provide evidence that pericyte α6-integrin controls PDGFRβ expression and AKT–mTOR signalling. Taken together, we show that pericyte α6β1-integrin regulates tumour blood vessels by both controlling PDGFRβ and basement membrane architecture. These data establish a novel dual role for pericyte α6-integrin as modulating the blood vessel phenotype during pathological angiogenesis.

          Abstract

          Summary: Mice with pericyte-specific deletion of α6-integrin had reduced pericyte blood vessel coverage, increased vessel leakiness and abnormal blood vessel architecture. α6-integrin also controls pericyte responses to PDGF-BB.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Integrins in angiogenesis and lymphangiogenesis.

          Blood vessels promote tumour growth, and both blood and lymphatic vessels facilitate tumour metastasis by serving as conduits for the transport of tumour cells to new sites. Angiogenesis and lymphangiogenesis are regulated by integrins, which are members of a family of cell surface receptors whose ligands are extracellular matrix proteins and immunoglobulin superfamily molecules. Select integrins promote endothelial cell migration and survival during angiogenesis and lymphangiogenesis, whereas other integrins promote pro-angiogenic macrophage trafficking to tumours. Several integrin-targeted therapeutic agents are currently in clinical trials for cancer therapy. Here, we review the evidence implicating integrins as a family of fundamental regulators of angiogenesis and lymphangiogenesis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.

            Angiopoietin-1 (Ang1) and vascular endothelial growth factor (VEGF) are endothelial cell-specific growth factors. Direct comparison of transgenic mice overexpressing these factors in the skin revealed that the VEGF-induced blood vessels were leaky, whereas those induced by Ang1 were nonleaky. Moreover, vessels in Ang1-overexpressing mice were resistant to leaks caused by inflammatory agents. Coexpression of Ang1 and VEGF had an additive effect on angiogenesis but resulted in leakage-resistant vessels typical of Ang1. Ang1 therefore may be useful for reducing microvascular leakage in diseases in which the leakage results from chronic inflammation or elevated VEGF and, in combination with VEGF, for promoting growth of nonleaky vessels.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

              The functional role of pericytes in cancer progression remains unknown. Clinical studies suggest that low numbers of vessel-associated pericytes correlated with a drop in overall survival of patients with invasive breast cancer. Using genetic mouse models or pharmacological inhibitors, pericyte depletion suppressed tumor growth but enhanced metastasis. Pericyte depletion was further associated with increased hypoxia, epithelial-to-mesenchymal transition (EMT), and Met receptor activation. Silencing of Twist or use of a Met inhibitor suppressed hypoxia and EMT/Met-driven metastasis. In addition, poor pericyte coverage coupled with high Met expression in cancer cells speculates the worst prognosis for patients with invasive breast cancer. Collectively, our study suggests that pericytes within the primary tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis. Copyright © 2012 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Journal
                J Cell Sci
                J. Cell. Sci
                JCS
                joces
                Journal of Cell Science
                The Company of Biologists Ltd
                0021-9533
                1477-9137
                1 May 2017
                1 May 2017
                : 130
                : 9
                : 1583-1595
                Affiliations
                [1 ]Adhesion and Angiogenesis Laboratory, Centre for Tumour Biology, Barts Cancer Institute - A CRUK Centre of Excellence, Queen Mary University of London , Charterhouse Square, London EC1M 6BQ, UK
                [2 ]Laboratory for Molecular Neuro-Oncology, Dept. of Neurology, University Hospital Zurich , Frauenklinikstrasse 26, Zurich CH-8091, Switzerland
                [3 ]IGBMC, UMR 7104, INSERM U964, Université de Strasbourg , BP. 10142, 1, Rue Laurent Fries, Illkirch Cedex 67404, France
                [4 ]Cancer Research UK Edinburgh Centre, University of Edinburgh , Crewe Road South, Edinburgh EH4 2XR, UK
                Author notes
                [*]

                These authors contributed equally to this work

                []Author for correspondence ( l.reynolds@ 123456qmul.ac.uk )
                Author information
                http://orcid.org/0000-0001-6075-1808
                Article
                JCS197848
                10.1242/jcs.197848
                5450232
                28289267
                8b248fc7-97c3-4162-bb76-156f2c8c8fc5
                © 2017. Published by The Company of Biologists Ltd

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

                History
                : 23 September 2016
                : 8 March 2017
                Funding
                Funded by: Cancer Research UK, http://dx.doi.org/10.13039/501100000289;
                Award ID: C8218/A18673
                Categories
                Research Article

                Cell biology
                integrin,pericyte,tumour growth,angiogenesis
                Cell biology
                integrin, pericyte, tumour growth, angiogenesis

                Comments

                Comment on this article